Abstract
AMP-activated protein kinase (AMPK ), a phylogenetically conserved serine/threonine protein kinase, is a major regulator of cellular and whole-body energy homeostasis that coordinates metabolic pathways in order to balance nutrient supply with energy demand. It is now recognized that pharmacological activation of AMPK improves blood glucose homeostasis, lipid profile, and blood pressure in insulin-resistant rodents. Indeed, AMPK activation mimics the beneficial effects of physical activity or those of calorie restriction by acting on multiple cellular targets. In addition, it is now demonstrated that AMPK is one of the probable (albeit indirect) targets of major antidiabetic drugs including the biguanides (metformin ) and thiazolidinedione s, as well as of insulin-sensitizing adipokines (e.g., adiponectin ). Taken together, such findings highlight the logic underlying the concept of targeting the AMPK pathway for the treatment of metabolic syndrome and type 2 diabetes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alberti KG, Zimmet PZ (1998) New diagnostic criteria and classification of diabetes–again? Diabet Med 15:535–536
Andersson U, Filipsson K et al (2004) AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 279:12005–12008
Andreelli F, Foretz M et al (2006) Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 147:2432–2441
Anthonsen MW, Ronnstrand L et al (1998) Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J Biol Chem 273:215–221
Assifi MM, Suchankova G et al (2005) AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats. Am J Physiol Endocrinol Metab 289:E794–E800
Banerjee RR, Rangwala SM et al (2004) Regulation of fasted blood glucose by resistin. Science 303:1195–1198
Banks AS, Kon N et al (2008) SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 8:333–341
Barnes BR, Marklund S et al (2004) The 5′-AMP-activated protein kinase gamma3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. J Biol Chem 279:38441–38447
Baur JA, Pearson KJ et al (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342
Bergeron R, Russell RR 3rd et al (1999) Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am J Physiol 276:E938–E944
Bergeron R, Previs SF et al (2001a) Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50:1076–1082
Bergeron R, Ren JM et al (2001b) Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab 281:E1340–E1346
Boon H, Bosselaar M et al (2008) Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients. Diabetologia 51:1893–1900
Bordone L, Motta MC et al (2006) Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 4:e31
Bruce CR, Mertz VA et al (2005) The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes 54:3154–3160
Buhl ES, Jessen N et al (2002) Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 51:2199–2206
Butler AE, Janson J et al (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110
Canto C, Gerhart-Hines Z et al (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458:1056–1060
Canto C, Jiang LQ et al (2010) Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 11:213–219
Carattino MD, Edinger RS et al (2005) Epithelial sodium channel inhibition by AMP-activated protein kinase in oocytes and polarized renal epithelial cells. J Biol Chem 280:17608–17616
Carey DG, Cowin GJ et al (2002) Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes Res 10:1008–1015
Carey AL, Steinberg GR et al (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase . Diabetes 55:2688–2697
Chen ZP, Mitchelhill KI et al (1999) AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 443:285–289
Chen ZP, McConell GK et al (2000) AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab 279:E1202–E1206
Chen Z, Peng IC et al (2009) AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 104:496–505
Clarke PR, Hardie DG (1990) Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver. EMBO J 9:2439–2446
Collins QF, Liu HY et al (2007) Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase . J Biol Chem 282:30143–30149
Cool B, Zinker B et al (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3:403–416
Corton JM, Gillespie JG et al (1995) 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229:558–565
da Silva Xavier G, Leclerc I et al (2003) Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem J 371:761–774
Dasgupta B, Milbrandt J (2007) Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 104:7217–7222
Daval M, Diot-Dupuy F et al (2005) Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J Biol Chem 280:25250–25257
Davis BJ, Xie Z et al (2006) Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase . Diabetes 55:496–505
DeFronzo RA, Tripathy D (2009) Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32(Suppl 2):S157–S163
Donath MY, Ehses JA et al (2005) Mechanisms of beta-cell death in type 2 diabetes. Diabetes 54(Suppl 2):S108–S113
Dreyer HC, Drummond MJ et al (2008) Resistance exercise increases human skeletal muscle AS160/TBC1D4 phosphorylation in association with enhanced leg glucose uptake during postexercise recovery. J Appl Physiol 105:1967–1974
Dyck JR, Lopaschuk GD (2006) AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol 574:95–112
Eckel RH, Grundy SM et al (2005) The metabolic syndrome. Lancet 365:1415–1428
El-Assaad W, Buteau J et al (2003) Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 144:4154–4163
Eto K, Yamashita T et al (2002) Genetic manipulations of fatty acid metabolism in beta-cells are associated with dysregulated insulin secretion. Diabetes 51(Suppl 3):S414–S420
Evans AM, Mustard KJ et al (2005) Does AMP-activated protein kinase couple inhibition of mitochondrial oxidative phosphorylation by hypoxia to calcium signaling in O2-sensing cells? J Biol Chem 280:41504–41511
Febbraio MA, Pedersen BK (2005) Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exerc Sport Sci Rev 33:114–119
Fisher JS, Gao J et al (2002) Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab 282:E18–E23
Fonseca VA (2009) Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32(Suppl 2):S151–S156
Foretz M, Carling D et al (1998) AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem 273:14767–14771
Foretz M, Ancellin N et al (2005) Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver . Diabetes 54:1331–1339
Fraser SA, Mount PF et al (2003) Inhibition of the Na-K-2Cl cotransporter by novel interaction with the metabolic sensor AMP-activated protein kinase . J Am Soc Nephrol 14:545A
Fryer LG, Parbu-Patel A et al (2002) The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277:25226–25232
Fujii N, Ho RC et al (2008) Ablation of AMP-activated protein kinase alpha2 activity exacerbates insulin resistance induced by high-fat feeding of mice. Diabetes 57:2958–2966
Garton AJ, Yeaman SJ (1990) Identification and role of the basal phosphorylation site on hormone-sensitive lipase. Eur J Biochem 191:245–250
Garton AJ, Campbell DG et al (1989) Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase . A possible antilipolytic mechanism. Eur J Biochem 179:249–254
Gledhill JR, Montgomery MG et al (2007) Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci USA 104:13632–13637
Glund S, Deshmukh A et al (2007) Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 56:1630–1637
Glund S, Treebak JT et al (2009) Role of adenosine 5'-monophosphate-activated protein kinase in interleukin-6 release from isolated mouse skeletal muscle. Endocrinology 150:600–606
Hammer S, Snel M et al (2008) Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 52:1006–1012
Hayashi T, Hirshman MF et al (1998) Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 47:1369–1373
Higa M, Zhou YT et al (1999) Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 96:11513–11518
Holmes BF, Kurth-Kraczek EJ et al (1999) Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol 87:1990–1995
Holmes BF, Lang DB et al (2004) AMP kinase is not required for the GLUT4 response to exercise and denervation in skeletal muscle. Am J Physiol Endocrinol Metab 287:E739–E743
Hou X, Xu S et al (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase . J Biol Chem 283:20015–20026
Howitz KT, Bitterman KJ et al (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191–196
Iglesias MA, Ye JM et al (2002) AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 51:2886–2894
Jager S, Handschin C et al (2007) AMP-activated protein kinase (AMPK ) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 104:12017–12022
Jazet IM, Schaart G et al (2008) Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients. Diabetologia 51:309–319
Jorgensen SB, Wojtaszewski JF et al (2005) Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle. FASEB J 19:1146–1148
Kahn SE, Hull RL et al (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846
Kaiser N, Leibowitz G et al (2003) Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 16:5–22
Kamohara S, Burcelin R et al (1997) Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389:374–377
Katsuki A, Sumida Y et al (2003) Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care 26:2341–2344
Kefas BA, Cai Y et al (2003a) AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol 30:151–161
Kefas BA, Heimberg H et al (2003b) AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase . Diabetologia 46:250–254
Kelly M, Keller C et al (2004) AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 320:449–454
Kim MS, Park JY et al (2004) Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase . Nat Med 10:727–733
Kim WH, Lee JW et al (2007) AICAR potentiates ROS production induced by chronic high glucose: roles of AMPK in pancreatic beta-cell apoptosis. Cell Signal 19:791–805
Knowler WC, Barrett-Connor E et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . N Engl J Med 346:393–403
Koistinen HA, Galuska D et al (2003) 5-amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. Diabetes 52:1066–1072
Kola B, Hubina E et al (2005) Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase . J Biol Chem 280:25196–25201
Koo SH, Flechner L et al (2005) The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437:1109–1111
Kubota N, Terauchi Y et al (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863–25866
Kurth-Kraczek EJ, Hirshman MF et al (1999) 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48:1667–1671
Lagouge M, Argmann C et al (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109–1122
Lan F, Cacicedo JM et al (2008) SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1 . Possible role in AMP-activated protein kinase activation. J Biol Chem 283:27628–27635
Larson-Meyer DE, Heilbronn LK et al (2006) Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 29:1337–1344
Lau KS, Grange RW et al (2000) nNOS and eNOS modulate cGMP formation and vascular response in contracting fast-twitch skeletal muscle. Physiol Genomics 2:21–27
Leclerc I, Kahn A et al (1998) The 5′-AMP-activated protein kinase inhibits the transcriptional stimulation by glucose in liver cells, acting through the glucose response complex. FEBS Lett 431:180–184
Leclerc I, Lenzner C et al (2001) Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase . Diabetes 50:1515–1521
Leclerc I, Woltersdorf WW et al (2004) Metformin, but not leptin , regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab 286:E1023–E1031
Lee WJ, Lee IK et al (2005a) Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase . Arterioscler Thromb Vasc Biol 25:2488–2494
Lee WJ, Song KH et al (2005b) Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun 332:885–891
Lee-Young RS, Griffee SR et al (2009) Skeletal muscle AMP-activated protein kinase is essential for the metabolic response to exercise in vivo. J Biol Chem 284:23925–23934
Lee-Young RS, Ayala JE et al (2010) Endothelial nitric oxide synthase is central to skeletal muscle metabolic regulation and enzymatic signaling during exercise in vivo. Am J Physiol Regul Integr Comp Physiol 298:R1399–R1408
Liao Y, Takashima S et al (2005) Exacerbation of heart failure in adiponectin -deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 67:705–713
Lihn AS, Jessen N et al (2004) AICAR stimulates adiponectin and inhibits cytokines in adipose tissue. Biochem Biophys Res Commun 316:853–858
Lin HZ, Yang SQ et al (2000) Metformin reverses fatty liver disease in obese, leptin -deficient mice. Nat Med 6:998–1003
Lira VA, Soltow QA et al (2007) Nitric oxide increases GLUT4 expression and regulates AMPK signaling in skeletal muscle. Am J Physiol Endocrinol Metab 293:E1062–E1068
Lochhead PA, Salt IP et al (2000) 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 49:896–903
Luo Z, Saha AK et al (2005) AMPK , the metabolic syndrome and cancer. Trends Pharmacol Sci 26:69–76
Lupi R, Del Guerra S et al (2002) Lipotoxicity in human pancreatic islets and the protective effect of metformin . Diabetes 51(Suppl 1):S134–S137
Maeda N, Takahashi M et al (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin , an adipose-derived protein. Diabetes 50:2094–2099
Majithiya JB, Balaraman R (2006) Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats. Life Sci 78:2615–2624
Martin TL, Alquier T et al (2006) Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. J Biol Chem 281:18933–18941
Matejkova O, Mustard KJ et al (2004) Possible involvement of AMP-activated protein kinase in obesity resistance induced by respiratory uncoupling in white fat. FEBS Lett 569:245–248
Maxwell AJ, Schauble E et al (1998) Limb blood flow during exercise is dependent on nitric oxide. Circulation 98:369–374
Merrill GF, Kurth EJ et al (1997) AICA riboside increases AMP-activated protein kinase , fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 273:E1107–E1112
Michael LF, Wu Z et al (2001) Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci USA 98:3820–3825
Milne JC, Lambert PD et al (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712–716
Minokoshi Y, Haque MS et al (1999) Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes 48:287–291
Minokoshi Y, Kim YB et al (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase . Nature 415:339–343
Minokoshi Y, Alquier T et al (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428:569–574
Mootha VK, Lindgren CM et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273
Moule SK, Denton RM (1998) The activation of p38 MAPK by the beta-adrenergic agonist isoproterenol in rat epididymal fat cells. FEBS Lett 439:287–290
Moynihan KA, Grimm AA et al (2005) Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab 2:105–117
Muoio DM, Seefeld K et al (1999) AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J 338(Pt 3):783–791
Murry CE, Jennings RB et al (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124–1136
Musi N, Fujii N et al (2001) AMP-activated protein kinase (AMPK ) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes 50:921–927
Narkar VA, Downes M et al (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell 134:405–415
Nathan DM, Buse JB et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30
Nawrocki AR, Rajala MW et al (2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281:2654–2660
Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37:1202–1219
Nieto-Vazquez I, Fernandez-Veledo S et al (2008) Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 57:3211–3221
Nishino Y, Miura T et al (2004) Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc Res 61:610–619
Nyblom HK, Sargsyan E et al (2008) AMP-activated protein kinase agonist dose dependently improves function and reduces apoptosis in glucotoxic beta-cells without changing triglyceride levels. J Mol Endocrinol 41:187–194
Orci L, Cook WS et al (2004) Rapid transformation of white adipocytes into fat-oxidizing machines. Proc Natl Acad Sci USA 101:2058–2063
Ouchi N, Kihara S et al (2001) Adipocyte-derived plasma protein, adiponectin , suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057–1063
Pacholec M, Bleasdale JE et al (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1 . J Biol Chem 285:8340–8351
Palanivel R, Sweeney G (2005) Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin. FEBS Lett 579:5049–5054
Pan XR, Li GW et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544
Park H, Kaushik VK et al (2002) Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem 277:32571–32577
Petersen KF, Befroy D et al (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance . Science 300:1140–1142
Phillips SA, Ciaraldi TP et al (2003) Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52:667–674
Picard F, Kurtev M et al (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429:771–776
Pischon T, Girman CJ et al (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737
Pold R, Jensen LS et al (2005) Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 54:928–934
Prentki M, Joly E et al (2002) Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 51(Suppl 3):S405–S413
Rhodes CJ (2005) Type 2 diabetes-a matter of beta-cell life and death? Science 307:380–384
Riboulet-Chavey A, Diraison F et al (2008) Inhibition of AMP-activated protein kinase protects pancreatic beta-cells from cytokine-mediated apoptosis and CD8+ T-cell-induced cytotoxicity. Diabetes 57:415–423
Richards SK, Parton LE et al (2005) Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo. J Endocrinol 187:225–235
Roberts CK, Barnard RJ et al (1999) Acute exercise increases nitric oxide synthase activity in skeletal muscle. Am J Physiol 277:E390–E394
Rodgers JT, Puigserver P (2007) Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA 104:12861–12866
Rossmeisl M, Barbatelli G et al (2002) Expression of the uncoupling protein 1 from the aP2 gene promoter stimulates mitochondrial biogenesis in unilocular adipocytes in vivo. Eur J Biochem 269:19–28
Rubin LJ, Magliola L et al (2005) Metabolic activation of AMP kinase in vascular smooth muscle. J Appl Physiol 98:296–306
Russell RR 3rd, Li J et al (2004) AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114:495–503
Saha AK, Avilucea PR et al (2004) Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 314:580–585
Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799–806
Sanders MJ, Grondin PO et al (2007) Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J 403:139–148
Sell H, Dietze-Schroeder D et al (2006) Cytokine secretion by human adipocytes is differentially regulated by adiponectin , AICAR , and troglitazone. Biochem Biophys Res Commun 343:700–706
Shaw RJ, Lamia KA et al (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin . Science 310:1642–1646
Shibata R, Ouchi N et al (2004a) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10:1384–1389
Shibata R, Ouchi N et al (2004b) Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem 279:28670–28674
Shibata R, Sato K et al (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK - and COX-2-dependent mechanisms. Nat Med 11:1096–1103
Smith AC, Bruce CR et al (2005) AMP kinase activation with AICAR further increases fatty acid oxidation and blunts triacylglycerol hydrolysis in contracting rat soleus muscle. J Physiol 565:547–553
Song XM, Fiedler M et al (2002) 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 45:56–65
Steinberg GR, Kemp BE (2009) AMPK in health and disease. Physiol Rev 89:1025–1078
Steinberg GR, Michell BJ et al (2006) Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 4:465–474
Stephens TJ, Chen ZP et al (2002) Progressive increase in human skeletal muscle AMPKalpha2 activity and ACC phosphorylation during exercise. Am J Physiol Endocrinol Metab 282:E688–E694
Stoppani J, Hildebrandt AL et al (2002) AMP-activated protein kinase activates transcription of the UCP3 and HKII genes in rat skeletal muscle. Am J Physiol Endocrinol Metab 283:E1239–E1248
Sullivan JE, Brocklehurst KJ et al (1994) Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR , a cell-permeable activator of AMP-activated protein kinase . FEBS Lett 353:33–36
Sun C, Zhang F et al (2007) SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 6:307–319
Sun G, Tarasov AI et al (2010) Ablation of AMP-activated protein kinase alpha1 and alpha2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo. Diabetologia 53(5):924–936
Suter M, Riek U et al (2006) Dissecting the role of 5′-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase . J Biol Chem 281:32207–32216
Suzuki A, Okamoto S et al (2007) Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase . Mol Cell Biol 27:4317–4327
Tomas E, Tsao TS et al (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309–16313
Treebak JT, Birk JB et al (2007) AS160 phosphorylation is associated with activation of alpha2beta2gamma1- but not alpha2beta2gamma3-AMPK trimeric complex in skeletal muscle during exercise in humans. Am J Physiol Endocrinol Metab 292:E715–E722
Tuomilehto J, Lindstrom J et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350
U.K. Prospective Diabetes Study Group (1995) U.K. prospective diabetes study 16: Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 44:1249–1258
Um JH, Park SJ et al (2010) AMP-activated protein kinase -deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59:554–563
Unger RH (1995) Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44:863–870
Van Gaal LF, Mertens IL et al (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444:875–880
Viana AY, Sakoda H et al (2006) Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. Diabetes Res Clin Pract 73:135–142
Viollet B, Andreelli F et al (2003) Physiological role of AMP-activated protein kinase (AMPK ): insights from knockout mouse models. Biochem Soc Trans 31:216–219
Wang X, Zhou L et al (2007) Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Life Sci 81:160–165
Watt MJ, Holmes AG et al (2006) Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab 290:E500–E508
Weiss EP, Racette SB et al (2006) Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr 84:1033–1042
Willett WC, Dietz WH et al (1999) Guidelines for healthy weight. N Engl J Med 341:427–434
Winder WW, Hardie DG (1999) AMP-activated protein kinase , a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 277:E1–E10
Winder WW, Holmes BF et al (2000) Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 88:2219–2226
Wing RR, Goldstein MG et al (2001) Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care 24:117–123
Witters LA, Gao G et al (1994) Hepatic 5'-AMP-activated protein kinase : zonal distribution and relationship to acetyl-CoA carboxylase activity in varying nutritional states. Arch Biochem Biophys 308:413–419
Woods A, Azzout-Marniche D et al (2000) Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol 20:6704–6711
Xu A, Wang Y et al (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112:91–100
Yamauchi T, Kamon J et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946
Yamauchi T, Kamon J et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase . Nat Med 8:1288–1295
Yamauchi T, Kamon J et al (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461–2468
Zang M, Xu S et al (2006) Polyphenols stimulate AMP-activated protein kinase , lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55:2180–2191
Zarrinpashneh E, Carjaval K et al (2006) Role of the alpha2 isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia. Am J Physiol Heart Circ Physiol 291(6):H2875–H2883
Zhang J, Xie Z et al (2008) Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. J Biol Chem 283:27452–27461
Zhou M, Lin BZ et al (2000) UCP-3 expression in skeletal muscle: effects of exercise, hypoxia, and AMP-activated protein kinase . Am J Physiol Endocrinol Metab 279:E622–E629
Zhou G, Myers R et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167–1174
Zhou L, Wang X et al (2008) Berberine acutely inhibits insulin secretion from beta-cells through 3′, 5′-cyclic adenosine 5′-monophosphate signaling pathway. Endocrinology 149:4510–4518
Zong H, Ren JM et al (2002) AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci USA 99:15983–15987
Zwetsloot KA, Westerkamp LM et al (2008) AMPK regulates basal skeletal muscle capillarization and VEGF expression, but is not necessary for the angiogenic response to exercise. J Physiol 586:6021–6035
Acknowledgments
This work was supported by the European Commission integrated project (LSHM-CT-2004-005272/exgenesis), Agence Nationale de la Recherche (ANR-06-PHYSIO-026), Association Française contre les Myopathies (AFM), Association pour l’Etude des Diabètes et des Maladies Métaboliques (ALFEDIAM), and Institut Benjamin Delessert.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Viollet, B., Andreelli, F. (2011). AMP-Activated Protein Kinase and Metabolic Control. In: Schwanstecher, M. (eds) Diabetes - Perspectives in Drug Therapy. Handbook of Experimental Pharmacology, vol 203. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-17214-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-17214-4_13
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-17213-7
Online ISBN: 978-3-642-17214-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)